Pharmaceutical Services and global health governance in times of COVID-19

Ribeiro, Alane Andrelino; Ricardi, Luciani Martins; Pontes, Marcela Amaral; Leite, Silvana Nair

doi:10.1590/0103-1104202213318I

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ESSAY • Saúde debate 46 (133) • Apr-Jun 2022 • https://doi.org/10.1590/0103-1104202213318I copy

Pharmaceutical Services and global health governance in times of COVID-19

Authorship SCIMAGO INSTITUTIONS RANKINGS

ABSTRACT

This essay addresses how and at what levels Pharmaceutical Services is affected by the dynamics of global health governance, and how it correlates with geopolitical and socioeconomic aspects. It attempts to go beyond access to medicines and health products, as well as to address the rational use of medicines, the impact in antimicrobial resistance and in people’s health. Furthermore, it debates how Pharmaceutical Services can be seen in this context.

KEYWORDS
Pharmaceutical Services; Global health; COVID-19

Theme	Document
Intellectual property, innovation and public health rights	WHO. World Health Assembly. WHA 56.27. Intellectual property rights, innovation and public health Resolution. WHA 28 May 2003. WHO. World Health Assembly. WHA61.21. Global strategy and plan of action on public health, innovation and intellectual property. 2008. http://mobile.wpro.who.int/health_research/policy_documents/global_strategy_may2008.pdf WHO. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. 2011. https://www.who.int/phi/publications/Global_Strategy_Plan_Action.pdf WHO. World Health Assembly. WHA68.18: Global strategy and plan of action on public health, innovation and intellectual property. 2015. WHO. World Health Assembly. WHA69.23: Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. 2016. WHO. World Health Assembly. WHA71.9: Global strategy and plan of action on public health, innovation and intellectual property: overall programme review. 2017. WHO. World Health Assembly. WHA71.13: Global strategy and plan of action on public health, innovation and intellectual property: overall programme review. 2018. WHO. World Health Assembly. Resolution WHA73.1: COVID-19 response. 2020. https://apps.who.int/gb/ebwha/pdffiles/WHA73/A73_R1-en.pdf
Expanding access to medicines and other technologies	UN. united Nations General Assembly. Resolution UN A/RES/74/274. Resolution adopted by the General Assembly on 20 April 2020. International cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19. 2020. https://undocs.org/en/A/RES/74/274 UN. united Nations General Assembly. Resolution UN S/RES/2565 (2021). Resolution adopted by the General Assembly on 26 February 2021. 2021. https://undocs.org/en/S/RES/2565(2021) WHO. World Health Assembly. WHA70.12: Cancer prevention and control in the context of an integrated approach. 2017. WHO. World Health Assembly. WHA71.8: Addressing the global shortage of, and access to, medicines and vaccines. 2018. WHO. World Health Organization. Roadmap for access to medicines, vaccines and health products 2019-2023: comprehensive support for access to medicines, vaccines and other health products. 2019a. ISbN 9789241517034. https://apps.who.int/iris/handle/10665/330145 WHO. Executive board. Report Eb 148/9. Expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices, diagnostics, assistive products, cell- and gene-based therapies and other health technologies; and improving the transparency of markets for medicines, vaccines, and other health products. 2020. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_9-en.pdf WHO. World Health Organization. Resolution WHA73.1: COVID-19 response. 2020. https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R1-en.pdf OEA. CP/doc. 5673/21 rev. 2. Organización de los Estados Americanos. Draft Resolution - The Equitable Distribution of Covid-19 Vaccines. http://www.oas.org/es/council/CP/documentation/var_documents/cpdoc/
Drug prices	WHO. World Health Organization. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly. 2018. https://apps.who.int/iris/handle/10665/277190?show=full WHO. World Health Organization. WHO guideline on country pharmaceutical pricing policies. 2020. ISbN: 9789240011878 https://www.who.int/publications-detail-redirect/9789240011878 WHO. World Health Organization. Fair pricing of medicines. 2021. https://www.who.int/medicines/access/fair_pricing/en/
Strengthening local production of medicines and other health technologies	WHO. World Health Organization. Resolution WHA 74.6. Strengthening local production of medicines and other health technologies to improve access Draft resolution proposed by China, Eswatini, Ethiopia, Ghana, Kenya, Namibia, Rwanda, South Africa, Sudan, Togo and Zimbabwe. 2021. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_CONF9-en.pdf
Strengthening the transparency of the pharmaceutical and other healthcare technologies market	WHO. World Health Organization. Resolution WHA 72.8. Improving the transparency of markets for medicines, vaccines, and other health products. 2019. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8-en.pdf WHO. Executive board. Report Eb 148/9. Expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices, diagnostics, assistive products, cell- and gene-based therapies and other health technologies; and improving the transparency of markets for medicines, vaccines, and other health products. 2020. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_9-en.pdf

Centro Brasileiro de Estudos de Saúde Av. Brasil, 4036, sala 802, 21040-361 Rio de Janeiro - RJ Brasil, Tel. 55 21-3882-9140, Fax.55 21-2260-3782 - Rio de Janeiro - RJ - Brazil
E-mail: revista@saudeemdebate.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Collaborators

Ribeiro AA (0000-0003-0233-9465)^* * Orcid (Open Researcher and Contributor ID). contributed to the design, planning, analysis and interpretation of data; review of the article text and approval of the final version of the manuscript. Ricardi LM (0000-0002-7500-0465)^* * Orcid (Open Researcher and Contributor ID). contributed to the analysis and interpretation of data and review of the article’s text. Pontes MA (0000-0002-0726-7475)^* * Orcid (Open Researcher and Contributor ID). contributed to the analysis and interpretation of data and revision of the article’s text. Leite SN (0000-0002-5258-9684)^* * Orcid (Open Researcher and Contributor ID). contributed to the planning, review of the article’s text and approval of the final version of the manuscript. ■